Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2001 December;26(4) > Minerva Endocrinologica 2001 December;26(4):289-92

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

  NEW DIAGNOSTIC AND THERAPEUTIC STRATEGIES: SOMATOSTATIN ANALOGS. Part II 

Minerva Endocrinologica 2001 December;26(4):289-92

Copyright © 2001 EDIZIONI MINERVA MEDICA

language: Italian

Comparison between integrated 24-hour concentrations of growth hormone, insulin-like growth factor I and prolactin in acromegalic patients treated with octreotide and patients and patients treated with octreotide LAR

Esposito V., Esposito D., Lo Iudice G.


PDF


The current therapeutic options for acromegalic patients (surgery, radiation therapy and/or pharmacological treatment) do not always lead to a definitive resolution of the disorder. Recently, octreotide (OC) and, more recently, octreotide LAR (OC-LAR), a new slow-release formulation of the long-acting somatostatin analog, have been regarded as the primary treatment for acromegaly. This study reports our observations of the integrated 24-hour concentrations of GH, IGF-I and prolactin (PRL) in acromegalic patients treated with octreotide (OC) and octreotide LAR (OC-LAR), highlighting lower percentages of apparent remissions.

top of page